Selected research
Industry Growth & Trends
Global Peptide Antibiotics Industry Growth and Trends Forecast to 2032
Market perspective
The global Peptide Antibiotics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Peptide Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Peptide Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Peptide Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Peptide Antibiotics include AMP Therapeutics, Hospira, Kasten, Madam Therapeutics, Pacgen Life Science Corporation, Phosphagenics, Savara Pharmaceuticals, Theravance and Vicuron Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Peptide Antibiotics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Peptide Antibiotics market size, estimates, and forecasts are presented in terms of sales volume (Tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Peptide Antibiotics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Peptide Antibiotics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Peptide Antibiotics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Peptide Antibiotics Market by Company
AMP Therapeutics
Hospira
Kasten
Madam Therapeutics
Pacgen Life Science Corporation
Phosphagenics
Savara Pharmaceuticals
Theravance
Vicuron Pharmaceuticals
GlaxoSmithKline
Pfizer
Eli Lilly
Novartis
Peptide Antibiotics Segment by Type
Ribosomal Synthesized Peptide Antibiotics
Non-Ribosomally Synthesized Peptide Antibiotics
Peptide Antibiotics Segment by Application
Pharma & Healthcare
Food Industry
Commodities
Other
Peptide Antibiotics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Antibiotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Antibiotics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Antibiotics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Antibiotics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Peptide Antibiotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ribosomal Synthesized Peptide Antibiotics
- Non-Ribosomally Synthesized Peptide Antibiotics
Applications
- Pharma & Healthcare
- Food Industry
- Commodities
- Other
Companies covered
- AMP Therapeutics
- Hospira
- Kasten
- Madam Therapeutics
- Pacgen Life Science Corporation
- Phosphagenics
- Savara Pharmaceuticals
- Theravance
- Vicuron Pharmaceuticals
- GlaxoSmithKline
- Pfizer
- Eli Lilly
- Novartis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Peptide Antibiotics Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Peptide Antibiotics Sales Estimates and Forecasts (2021-2032)
- 1.3 Peptide Antibiotics Market by Type
- 1.3.1 Ribosomal Synthesized Peptide Antibiotics
- 1.3.2 Non-Ribosomally Synthesized Peptide Antibiotics
- 1.4 Global Peptide Antibiotics Market Size by Type
- 1.4.1 Global Peptide Antibiotics Market Size Overview by Type (2021-2032)
- 1.4.2 Global Peptide Antibiotics Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Peptide Antibiotics Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Peptide Antibiotics Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Peptide Antibiotics Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Peptide Antibiotics Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Peptide Antibiotics Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Peptide Antibiotics Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Peptide Antibiotics Industry Trends
- 2.2 Peptide Antibiotics Industry Drivers
- 2.3 Peptide Antibiotics Industry Opportunities and Challenges
- 2.4 Peptide Antibiotics Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Peptide Antibiotics Revenue (2021-2026)
- 3.2 Global Top Players by Peptide Antibiotics Sales (2021-2026)
- 3.3 Global Top Players by Peptide Antibiotics Price (2021-2026)
- 3.4 Global Peptide Antibiotics Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Peptide Antibiotics Major Company Production Sites & Headquarters
- 3.6 Global Peptide Antibiotics Company, Product Type & Application
- 3.7 Global Peptide Antibiotics Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Peptide Antibiotics Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Peptide Antibiotics Players Market Share by Revenue in 2025
- 3.8.3 2025 Peptide Antibiotics Tier 1, Tier 2, and Tier 3
4 Peptide Antibiotics Regional Status and Outlook
- 4.1 Global Peptide Antibiotics Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Peptide Antibiotics Historic Market Size by Region
- 4.2.1 Global Peptide Antibiotics Sales in Volume by Region (2021-2026)
- 4.2.2 Global Peptide Antibiotics Sales in Value by Region (2021-2026)
- 4.2.3 Global Peptide Antibiotics Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Peptide Antibiotics Forecasted Market Size by Region
- 4.3.1 Global Peptide Antibiotics Sales in Volume by Region (2027-2032)
- 4.3.2 Global Peptide Antibiotics Sales in Value by Region (2027-2032)
- 4.3.3 Global Peptide Antibiotics Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Peptide Antibiotics by Application
- 5.1 Peptide Antibiotics Market by Application
- 5.1.1 Pharma & Healthcare
- 5.1.2 Food Industry
- 5.1.3 Commodities
- 5.1.4 Other
- 5.2 Global Peptide Antibiotics Market Size by Application
- 5.2.1 Global Peptide Antibiotics Market Size Overview by Application (2021-2032)
- 5.2.2 Global Peptide Antibiotics Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Peptide Antibiotics Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Peptide Antibiotics Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Peptide Antibiotics Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Peptide Antibiotics Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Peptide Antibiotics Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Peptide Antibiotics Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 AMP Therapeutics
- 6.1.1 AMP Therapeutics Company Information
- 6.1.2 AMP Therapeutics Business Overview
- 6.1.3 AMP Therapeutics Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 AMP Therapeutics Peptide Antibiotics Product Portfolio
- 6.1.5 AMP Therapeutics Recent Developments
- 6.2 Hospira
- 6.2.1 Hospira Company Information
- 6.2.2 Hospira Business Overview
- 6.2.3 Hospira Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Hospira Peptide Antibiotics Product Portfolio
- 6.2.5 Hospira Recent Developments
- 6.3 Kasten
- 6.3.1 Kasten Company Information
- 6.3.2 Kasten Business Overview
- 6.3.3 Kasten Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Kasten Peptide Antibiotics Product Portfolio
- 6.3.5 Kasten Recent Developments
- 6.4 Madam Therapeutics
- 6.4.1 Madam Therapeutics Company Information
- 6.4.2 Madam Therapeutics Business Overview
- 6.4.3 Madam Therapeutics Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Madam Therapeutics Peptide Antibiotics Product Portfolio
- 6.4.5 Madam Therapeutics Recent Developments
- 6.5 Pacgen Life Science Corporation
- 6.5.1 Pacgen Life Science Corporation Company Information
- 6.5.2 Pacgen Life Science Corporation Business Overview
- 6.5.3 Pacgen Life Science Corporation Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Pacgen Life Science Corporation Peptide Antibiotics Product Portfolio
- 6.5.5 Pacgen Life Science Corporation Recent Developments
- 6.6 Phosphagenics
- 6.6.1 Phosphagenics Company Information
- 6.6.2 Phosphagenics Business Overview
- 6.6.3 Phosphagenics Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Phosphagenics Peptide Antibiotics Product Portfolio
- 6.6.5 Phosphagenics Recent Developments
- 6.7 Savara Pharmaceuticals
- 6.7.1 Savara Pharmaceuticals Company Information
- 6.7.2 Savara Pharmaceuticals Business Overview
- 6.7.3 Savara Pharmaceuticals Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 Savara Pharmaceuticals Peptide Antibiotics Product Portfolio
- 6.7.5 Savara Pharmaceuticals Recent Developments
- 6.8 Theravance
- 6.8.1 Theravance Company Information
- 6.8.2 Theravance Business Overview
- 6.8.3 Theravance Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 Theravance Peptide Antibiotics Product Portfolio
- 6.8.5 Theravance Recent Developments
- 6.9 Vicuron Pharmaceuticals
- 6.9.1 Vicuron Pharmaceuticals Company Information
- 6.9.2 Vicuron Pharmaceuticals Business Overview
- 6.9.3 Vicuron Pharmaceuticals Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 Vicuron Pharmaceuticals Peptide Antibiotics Product Portfolio
- 6.9.5 Vicuron Pharmaceuticals Recent Developments
- 6.10 GlaxoSmithKline
- 6.10.1 GlaxoSmithKline Company Information
- 6.10.2 GlaxoSmithKline Business Overview
- 6.10.3 GlaxoSmithKline Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 6.10.4 GlaxoSmithKline Peptide Antibiotics Product Portfolio
- 6.10.5 GlaxoSmithKline Recent Developments
- 6.11 Pfizer
- 6.11.1 Pfizer Company Information
- 6.11.2 Pfizer Business Overview
- 6.11.3 Pfizer Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 6.11.4 Pfizer Peptide Antibiotics Product Portfolio
- 6.11.5 Pfizer Recent Developments
- 6.12 Eli Lilly
- 6.12.1 Eli Lilly Company Information
- 6.12.2 Eli Lilly Business Overview
- 6.12.3 Eli Lilly Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 6.12.4 Eli Lilly Peptide Antibiotics Product Portfolio
- 6.12.5 Eli Lilly Recent Developments
- 6.13 Novartis
- 6.13.1 Novartis Company Information
- 6.13.2 Novartis Business Overview
- 6.13.3 Novartis Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 6.13.4 Novartis Peptide Antibiotics Product Portfolio
- 6.13.5 Novartis Recent Developments
7 North America by Country
- 7.1 North America Peptide Antibiotics Sales by Country
- 7.1.1 North America Peptide Antibiotics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Peptide Antibiotics Sales by Country (2021-2026)
- 7.1.3 North America Peptide Antibiotics Sales Forecast by Country (2027-2032)
- 7.2 North America Peptide Antibiotics Market Size by Country
- 7.2.1 North America Peptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Peptide Antibiotics Market Size by Country (2021-2026)
- 7.2.3 North America Peptide Antibiotics Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Peptide Antibiotics Sales by Country
- 8.1.1 Europe Peptide Antibiotics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Peptide Antibiotics Sales by Country (2021-2026)
- 8.1.3 Europe Peptide Antibiotics Sales Forecast by Country (2027-2032)
- 8.2 Europe Peptide Antibiotics Market Size by Country
- 8.2.1 Europe Peptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Peptide Antibiotics Market Size by Country (2021-2026)
- 8.2.3 Europe Peptide Antibiotics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Peptide Antibiotics Sales by Country
- 9.1.1 Asia-Pacific Peptide Antibiotics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Peptide Antibiotics Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Peptide Antibiotics Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Peptide Antibiotics Market Size by Country
- 9.2.1 Asia-Pacific Peptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Peptide Antibiotics Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Peptide Antibiotics Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Peptide Antibiotics Sales by Country
- 10.1.1 South America Peptide Antibiotics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Peptide Antibiotics Sales by Country (2021-2026)
- 10.1.3 South America Peptide Antibiotics Sales Forecast by Country (2027-2032)
- 10.2 South America Peptide Antibiotics Market Size by Country
- 10.2.1 South America Peptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Peptide Antibiotics Market Size by Country (2021-2026)
- 10.2.3 South America Peptide Antibiotics Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Peptide Antibiotics Sales by Country
- 11.1.1 Middle East and Africa Peptide Antibiotics Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Peptide Antibiotics Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Peptide Antibiotics Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Peptide Antibiotics Market Size by Country
- 11.2.1 Middle East and Africa Peptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Peptide Antibiotics Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Peptide Antibiotics Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Peptide Antibiotics Value Chain Analysis
- 12.1.1 Peptide Antibiotics Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Peptide Antibiotics Production Mode & Process
- 12.2 Peptide Antibiotics Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Peptide Antibiotics Distributors
- 12.2.3 Peptide Antibiotics Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst